Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer Protein

Cat. No. MHC-HM473




Description	
Source	Recombinant Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
	It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and ILAKFLHWL peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&ILAKFLHWL
Molecular Weight	The protein has a predicted MW of 50.60 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and	Storage
Formulation	Supplied as 0.22 µm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as

an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.

Assay Data

Bis-Tris PAGE




Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer Protein

Cat. No. MHC-HM473

ĸvoin



The purity of Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer is greater than 95% as determined by SEC-HPLC.